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ABSTRACT
Objective: The aim of the overall study was to determine the quality of life (QOL) and the factors that influence it in patients with diabetes mellitus 
(DM) in primary health care (PHC) Jetis 1, Bantul.
Methods: This cross-sectional study was conducted on 153 DM patients in PHC Jetis I, Bantul. Respondents were recruited by inclusion and exclusion 
criteria. Primary data on exposure to cigarette smoke, adherence with physical activity, perception of disease, and QOL are collected through 
interviews. Data were analyzed by a mean test for ratio scale data and Chi-square test.
Results: The results showed that the QOL and the level of adherence of DM patients in Puskesmas Jetis I were classified as very good. Male patients, 
elementary school graduates, normal body mass index (BMI), normal fasting blood sugar levels, adherent DM medication, and positive disease 
perception have a greater chance of having a better QOL. The mean of the random blood sugar and the fasting blood sugar levels exceeded the normal 
values, with 261.70 ± 121.15 mg/dl and 167.43 ± 10.23, respectively.
Conclusion: The QOL of DM patients in I Jetis PHC is very good. Men, normal BMI, adherent with medication therapy, and normal fasting sugar levels 
are associated with an increase in QOL.
Keywords: Quality of life, Diabetes mellitus, Adherence, Normal fasting blood sugar.
INTRODUCTION
Health-related quality of life (HRQOL) is a concept that is often 
used as a basis for evaluating acute and chronic disease medication 
surveillance programs including diabetes mellitus (DM) [1]. The World 
Health Organization defines QOL as individual perceptions of values, 
concepts, and cultures in which they live and are interconnected to 
achieve life goals and expectations [2-4]. Although the measurement of 
the patient’s QOL is subjective, HRQOL has been used as a method to 
evaluate the cost-effectiveness of therapy management. Assessment of 
the QOL of DM patients in primary health facilities in Indonesia has not 
become a priority, even though the patient’s QOL data can be used as an 
indicator of management success and management evaluation of DM 
patients management at the Puskesmas (Indonesia’s primary health 
facilities). In contrast to Indonesia, the quality-adjusted life year (QALY) 
assessment as one of the outcome parameters for DM management 
and the basis for policymaking in primary health facilities has been 
widely carried out in Asian and Southeast Asian countries [5] such as 
Malaysia [6] and Singapura [7].
The QOL reflects therapy success and supports disease management 
success. Study of DM patients’ QOL in primary health facilities is 
important because DM is a chronic disease, with its increasing 
incidence, prevalence, treatment costs, and complications every 
year [8]. The IDF Diabetes Atlas/ADA latest report [9] estimates that 
currently there are 415 million people with diabetes with a prevalence 
of 2.8–4.4%. The facts show that DM patients are susceptible to various 
complications [10,11] and decreased QOL [12]. In Southeast Asia, by 
2030 it is estimated that there will be 58.1 million people with more 
than 25% having less than the average QALY [13]. QALY assessment 
in DM patients needs to be done to achieve better governance to 
increase therapeutic success and decrease the complication incidence 
in Indonesia so that cost efficiency can be realized.
Chronic diseases, such as type 2 DM (T2DM), will cause medical, 
socioeconomic, and psychological problems that will limit the 
ability to engage in activities that will affect the QOL [14-18]. DM 
is a chronic disease characterized by an increase in blood sugar 
levels [19-22]. Uncontrolled blood sugar levels can cause acute or 
chronic complications [20,23]. T2DM requires long-term therapy to 
control blood sugar levels and prevent complications [24]. In addition, 
more than 50% of T2DM patients over the age of 65 experience 
functional disorders that affect their autonomy and QOL [25]. T2DM 
patients have been shown to have a higher risk for the incidence of 
nephropathy, retinopathy, hypertension, stroke, peripheral neuropathy, 
and heart failure due to their failure to control blood sugar levels [26]. 
In Indonesia, DM patients, in 2030, are estimated to reach 21.3 million 
people, 20–30% of them with uncontrolled blood sugar or therapy 
target not achieved.
The medication therapy targets (MTP) in T2DM not be met were not 
only caused by the inappropriate use of drugs but also by patients’ 
lifestyle and psychosocial problems. Pharmacists need to consider the 
most common MTPs when counseling patients with T2DM [27].
Many factors can be attributed to the QOL of DM patients. Research 
in Singapore and Malaysia shows that distress, poor sleep quality, 
and comorbidity are associated with a decrease in DM patients’ 
HRQOL [6,27-29]. It has been proven that controlled blood sugar levels 
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are an important factor in maintaining the QOL of DM patients [30]. 
Research in Singapore and Indonesia shows that both hypoglycemia and 
hyperglycemia conditions are associated with a decrease in the QOL of 
DM patients [31,32]. Factors that play a role in failure of blood glucose 
control such as patients’ medication adherence need to be considered 
in the care of DM patients in the primary health center (PHC) [33]. 
Blood glucose levels that are not appropriately controlled can cause 
both acute and chronic complications. As many as, 63.1% of patients 
with T2DM have a risk of developing hypertension complications. DM 
can trigger various complications and causes a decrease in QALY [34].
Non-adherence or nonconcordance in undergoing therapy is a problem 
that often occurs so that patients experience therapy failure [35] and 
decreased QOL [36]. Non-adherence can prolong the illness duration 
and severity [37-39]. Various studies have shown that patient adherence 
with chronic disease treatment is generally low at 50% or lower. Non-
adherence can be caused by various factors such as lack of knowledge 
and understanding of drugs and the use of drugs for therapy [40,41], 
complexity of drug regimens, drug costs, age (increased age is inversely 
proportional to medication adherence), lack of family/social support, 
and cognitive problems in geriatrics. Other factors that have been 
shown to be related to adherence are perceptions about the disease and 
duration of illness and psychological factors such as awareness, drug 
safety, and tolerability [42]. Therapy results will not reach optimal levels 
without patients’ awareness [43]. Several methods have been developed 
to assess therapeutic adherence. The self-report scale is generally used 
to assess adherence to the use of antidiabetic and antihypertensive 
drugs, and many have been modified for use in Indonesia [44-46]. The 
medication adherence rating scale (MARS) method is one of the methods 
of measuring adherence with tested validity and reliability and may be 
used in research in primary health facilities. Therefore, the relationship 
of blood sugar and therapy adherence with the QOL of T2DM patients in 
Puskesmas Jetis 1 Bantul needs to be examined.
METHOD
Research design and subjects
This study is an analytic observational study with a cross-sectional design 
of DM patients in Puskesmas Jetis 1, Bantul, Yogyakarta. Respondents 
were all T2DM patients who met the inclusion and exclusion criteria. 
Inclusion criteria included adult patients (1) both men and women 
aged 18 years or older, (2) diagnosed as DM patients who received 
medication at the study site during the study period, and (3) consensual 
to be the study subjects. This study excluded DM patients diagnosed 
with hearing loss, pregnancy, kidney disorders, complications or a 
history of comorbid TB, HIV AIDS, heart failure, coronary heart disease, 
endocrine disorders (hypothyroidism or hyperthyroidism), chronic 
musculoskeletal disorders, or mental disorders.
Research protocols and inform consent forms were reviewed by the 
Medical and Health Science Faculty, Universitas Muhammadiyah 
Yogyakarta health research Ethics Committee and have received ethical 
clearance. This research has also obtained research permission from the 
Bantul Regency Regional Development Planning Agency (BAPPEDA).
Sample size
The number of all T2DM patients in Jetis I PHC based on the database 
was 216. The sample size is calculated with the Lemeshow formula 
below:
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wherein = sample size, Za = standard deviates from type I errors = 1.96, 
Zb = standard deviates from type II errors = 0.84 and OR = Minimum 
odds ratio that is considered significant = 2.8, where Px = proportion 
of exposure or proportion of risk factors =0.5 and Py = proportion of 
effects or proportions of dependent variables = 0.5. Based on the results 
of the calculations, the number of samples involved was 120 patients.
Data types and sources
The type of data in this study is primary and secondary data. Primary data 
were obtained through interviews using structured and observational 
questionnaires or laboratory examinations, while secondary data 
were collected from medical records. Primary data include life habits 
(exercise, medication adherence, QOL, type of work, education history, 
and marital status). Another primary data are fasting blood sugar levels 
obtained through laboratory examination. Secondary data include DM 
diagnosis in medical records, illness history, and treatment history in 
the past 3 months and clinical manifestations that occur.
Research variables and operational definitions
Variables in this study include independent variables, namely clinical 
outcomes (fasting blood sugar levels and blood pressure), medication 
adherence, exposure to cigarette smoke, anti-DM drugs, and comorbid 
diseases and the dependent variables include patients’ QOL using the 
SF-36 questionnaire form.
Operational variable definition
The independent variables in this study were blood sugar levels, 
medication adherence, and exposure to cigarette smoke. The 
dependent variable in the study is the patients’ QOL. The preparation 
of operational variable definitions is done to determine the appropriate 
data collection tool [47] (Table 1).
Research instruments and procedures
Research instruments
Questionnaire
Questionnaires used in this study include: (1) Respondents’ 
characteristics questionnaire to obtain primary data from patients in the 
form of demographic data (education, marital status, and occupation) 
and life habits (smoking and exercise), (2) MARS questionnaire 
to assess patient adherence in undergoing anti-DM drug therapy, 
and (3) SF-36 questionnaire to assess the patient’s QOL. The SF-36, 
whose Indonesian version has been validated, is an instrument that has 
been used in various countries and used as a gold standard in assessing 
QOL because this instrument consists of 36 short questions covering 
various aspects, namely physical, emotional, social, physical health, 
emotional health, pain, fatigue, and general health aspects. Physical 
components consist of physical function, physical role, pain, and general 
health, while the mental component consists of the role of emotions, 
vitality, social function, and mental health. This questionnaire has three 
stages: Scoring, the average of each domain, and grouping components 
by domain. The average score range is 0–100 with a normative average 
score of 50 [48]. The validity and reliability of the SF-36 questionnaire 
were tested, and the results showed that this questionnaire could be 
used to measure QOL [49].
Data collection form
Data collection form is used to collect data taken from medical records 
or patient status which includes name, age, gender, hospital diagnosis 
data, treatment, and laboratory data.
Research procedure
The research procedure is divided into three stages, namely preparation, 
implementation, and end. (1). Preparation phase: In the first stage, the 
researcher took care of the licensing at the BAPPEDA, collected secondary 
data (including general description of Jetis 1 PHC, Bantul in Yogyakarta, 
number of visits, diabetes incidence from medical records, and other 
sources), developed protocols on filling out questionnaires and data 
collection forms and prepared supporting facilities and infrastructure 
(writing facilities, etc.). Data collectors were trained on how to use 
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questionnaires and data collection forms. (2) Implementation phase: 
This stage begins with subject recruitment, namely patients who are 
positively diagnosed with diabetes that meet the inclusion criteria. 
Prospective subjects then received an explanation of the purpose 
and benefits of the study. Patients who agreed to be the subject were 
asked to give a sign of approval by signing an informed consent form. 
Subsequently, the patient was interviewed, and the researcher filled out 
data recording forms, health assessment forms (patients’ demographic 
data) and data collection forms containing diagnoses, laboratory 
results, blood pressure, and medicines listed in the prescription. 
Following that, interviews were conducted to obtain data for the 
lifestyle questionnaire, treatment history, adherence questionnaire, 
and QOL questionnaire (3). The final stage: At this stage data analysis, 
report preparation, preparation of publication texts, and dissemination 
of results are carried out.
Data analysis
Univariate analysis was used to obtain an overview of the frequency 
distribution (proportion) of patients’ characteristics based on 
demographics and Chi-square test to determine the relationship 
between independent variables, namely age, body mass index (BMI), 
adherence, fasting sugar levels, and smoking status with patients’ QOL.
RESULTS AND DISCUSSION
Respondents’ characteristics
There were 153 DM patients in Jetis I PHC involved in the study. Their 
characteristics are presented in Table 2.
Table 2 shows that most of the respondents were women, aged over 
45 years, and had elementary school education. Clinical characteristics 
of DM patients at Jetis I PHC are presented in Table 3.
Table 3 shows that most DM patients in the PHC suffer from 
comorbidities between 1 and 4 types of disease. Hypertension is the 
most common comorbid disease found in 58 patients followed by 
dyslipidemia in 18 patients. Metformin is the most widely prescribed 
anti-DM drug for patients with 58.17%, followed by a combination of 
metformin and glimepiride with 32.68%.
Description of the patients’ clinical characteristics based on 
fasting blood sugar levels, medication adherence, and QOL
An overview of the DM patients’ clinical condition in I JetisPHC is 
presented in Table 4.
Table 4 shows that the average age of the patient was 57.39 years and 
the mean of the random blood sugar and the fasting blood sugar levels 
exceeded the normal values, with 261.70 ± 121.15 mg/dl and 167.43 ± 
10.23, respectively. Other clinical parameters are within normal limits. 
The average adherence score of 22.44 ± 2.99 was classified as adherent, 
and the average QOL of 73.81 ± 12.40 was categorized as good QOL 
(score range 51–75). Furthermore, the mean score of patients’ 
perceptions of DM can be categorized as good because it was <40.
Description of medication adherence behavior and QOL of patients
Patients’ distribution based on the level of adherence is presented in 
Table 5.
Table 5 indicates that most of the patients were adherent (80.39%), 
with a small proportion less and non-adherent. It is also known that 
most patients had a very good QOL (52.94%), followed by good QOL 
(41.83%) and relatively low QOL (5.23%).
Bivariate analysis of factors associated with QOL
Table 6 shows the analysis results of the relationship between 
demographic factors (age), clinical output (normal fasting glucose 
Table 1: Variables operational definitions and measurement scales
No Variables Operational definitions Measurement Categories Scales
1 Education Information on patients’ education levels obtained from interviews 
or health questionnaire. The levels are no school/elementary 
school (SD), junior high school (SMP), senior high school (SMA), DI, 
DIII, S1, S2, S3, and others.
1=No school/SD
2=SMP; 3=SMA4=D1-S1; 5=S2 
Ordinal
2 Profession Information on the patients’ type of work or profession in earning 
a living obtained from interviews or health questionnaire, 




6 Cigarette exposure Active smokers, namely patients who are currently smoking and 
have smoked at least 100 cigarettes (3–4 packs) in their lifetime, or 
passive smokers, namely patients who do not smoke but there are 




7 Adherence Measured with the MARS questionnaire with the highest score of 
25 and lowest of 0. The average adherence score is measured and 
then compiled in the following adherence ratings:
1. High adherence: 21–25
2. Moderate adherence: 16–20
3. Low adherence: <16







QOL is a state of well-being which is a combination of two 
components: The ability to carry out daily activities (reflecting 
physical function, emotional function, social function, physical 
condition, emotional state, pain, fatigue, and general health) 
and patient satisfaction at the levels of function and disease 
control (Gotay et al., 1992). The SF-36 is an instrument used to 
measure QOL with 36 short questions and 8 health domains and is 
available in the Indonesian version.
QOL scores are then classified into 4: Low, adequate, good, and 
very good. 1=Low (0–25); 2=Adequate (26–50); 3=Good (51–75); 
4=Very good (76–100). QOL is then categorized as good or not 
good.
1.Good QOL (score>75)
2. Not good QOL (score<75 or=75)
nominal 
9 Age The age of DM patients is obtained from medical record or 
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level), BMI, compliance level, and status of smoke exposure with 
patients’ QOL (QALY) status.
Table 6 indicates the factors associated with the very good QOL. 
Male, higher than elementary school education, and employed tend 
to increase the chances of having a very good QOL for respondents 
(p<0.05). In addition, BMI that is ≤25 is associated with very good QOL 
with an odds ratio (OR) of 2.17 (confidence interval [CI]: 1.02–4.60; 
p=0.04). Furthermore, fasting blood sugar levels and the number of 
single anti-DM drugs were associated with a very good QOL with an OR 
of 4.28 (CI 95%: 1.77–10.35; p=0.001) and 1.89 (CI 95%: 1.00–3.65; 
p=0.04). Medication adherence with anti-DM drugs has been shown to 
be associated with QOL with an OR of 2.2 (CI 95%: 1.1–4.42; p=0.02).
DISCUSSION
Based on the results of this study, T2DM patients’ QOL is influenced by 
many factors, namely (1) the pathobiological condition and DM degree or 
type, (2) comorbidity, (3) distress level, (4) anti-DM drugs and medication 
adherence, (5) lifestyle (exercise/physical activity habits, smoking), 
and (6) patient’s perception of DM. Other influencing factors include 
(a) age, because most patients are adults over the age of 40 and insulin 
resistance in type 2 diabetes tends to increase at the age of 40–65 years; 
(b) gender, because the QOL of women and men is different, where 
women generally have a lower QOL; and (c) level of education, because 
this is closely related to the processing of knowledge and information 
obtained. Education is an important factor in T2DM patients to be able 
to understand and manage independently; (d) socioeconomic status, 
because this is related to income, where low status can be a predictor of 
the patients’ low QOL; (e) duration of illness, because this is related to the 
level of anxiety that can lower the patient’s QOL; and (f) complications 
due to DM, both acute and chronic complications are serious problems 
because they can increase patients’ physical, psychological and social 
disability, and ultimately can affect patients’ QOL [36,50-55]. Al-Qasem 
et al. suggested that in addition to demographic factors (age, gender, and 
socioeconomic status), comorbidity and perception of disease, treatment 
regimen complexity also affects the patients’ QOL [39,56].
Patients’ medication adherence and QOL
The results of the univariate analysis revealed that most patients were 
very adherent in undergoing anti-DM drug therapy, and the results of the 
Tabel 2: Distribution of demographic characteristics of DM 
patients in Jetis I PHC, Bantul, Yogyakarta












Elementary school 90 (58.8)
Junior high school 21 (13.7)
Senior high school 25 (16.3)
University 17 (11.1)
Employment type



















Table 3: Distribution of Subject’s clinical characteristic (illness 
duration, presence of comorbidities, type and number of 
comorbidities and medications received by DM patients) at I 
Jetis PHC, Bantul, DI Yogyakarta
















No comorbidity 62 (31.8)
1 comorbidity 68 (34.9)
2 comorbidity 19 (9.7)








Table 4: Description of the demographic and clinical condition 
of DM patients (n=153) at I Jetis PHC, Bantul, DIY
Clinical Characteristic Unit Mean±SD Min‑max
Age Year 57.39±8.27 34-83
BMI Kg/m2 22.90±2.00 15-33
Fasting glucose level mmHg 167.43±10.23 40-330
Random glucose blood level mg/dl 261.70±121.15* 82-637
Compliment score 22.44±2.99 0-25
HRQALY score 73.81±12.40 0-100
DM: Diabetes mellitus
Table 5: Distribution of level of complience and QAL of DM 
patients in Jetis I PHC, Bantul DIY
Variable Frekuensi Persentase
Level of complient 
Obey 123 80.39
semi-obedient 25 16.34
not obedient 5 3.27
Level of QOL
pretty good (QALY score=26–50) 8 5.23
Good (QALY score=51–75) 64 41.83
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bivariate analysis showed that the patients’ adherence was associated to 
their QOL. Adherence to treatment regimens is generally defined more 
broadly to describe how patients use prescription drugs. The word 
adherence is much preferred by many health workers because the word 
compliance giving the impression that the patient follows the doctor’s 
instructions passively and the treatment plan is determined unilaterally 
by the doctor [41-44]. Dulmen et al. [4] defined medication adherence 
as a level of behavior in which patients use drugs and adhere to all 
the rules and advice recommended by health workers. The concept of 
adherence is often used in chronic diseases. There are various important 
terms to describe patient adherence, namely compliance is the patient’s 
behavior to follow what is recommended or requested by a doctor or 
health worker. The concept of compliance feels negative because it is 
similar to the attitude of being obedient or submitting to the direction of 
a health worker. In contrast, adherence is based on patients’ awareness 
that arises based on commitment, principles, and trust. Concordance is 
compliance that is formed as a result of discussions between patients 
and health workers or doctors to form an agreement or cooperation 
in taking treatment measures [52,53]. The concept of adherence is 
preferred by many health workers because compliance gives the 
impression that the patient follows the doctor’s instructions passively 
and the treatment plan is determined unilaterally by the doctor [54]. 
Factors that can influence the level of patient adherence have been 
identified in several studies. Sabaté (2003) claimed that adherence 
will increase with clear treatment instructions, individual beliefs and 
attitudes to heal, pleasant and authoritative health workers, social and 
family support, knowledge, minimum drug effects, simple treatment, 
affordable prices, and good relationships between health workers and 
patients [40,55]. In general, the factors related to the level of adherence 
in DM patients are age, education, patient knowledge about drugs and 
disease, social and economic status, therapeutic regimens, and patient 
interactions with health workers [56,57].
CONCLUSION
DM patients in Jetis I PHC, Bantul, have good QOL. Patients’ controlled 
fasting blood sugar levels and medication adherence in undergoing 
anti-DM drug therapy can increase the patients’ chance of having a 
good QOL.
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